Top Back to top

EBMT to track long-term outcome data for Kymriah®

by

The EBMT announces a new collaboration with Novartis Pharmaceuticals to study the long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies. Under the terms of the collaboration, EBMT will collect treatment and long-term safety and efficacy data from patients treated with Kymriah® (tisagenlecleucel) in both approved indications in the EBMT registry for cellular therapy in the European regions.